Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 44

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 44
---
 to employees, officers, consultants, directors, and other service providers that was
approved in 2021 (the “2021 Plan”). The 2021 Plan provides for the grant of non-qualified stock options, incentive stock
options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based
compensation. The 2021 Plan permits the Company’s board to change the type, terms, and conditions of awards as circumstances may
change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world
events.

    F-8

A
summary of the stock option activity during the period ended June 30, 2025, is presented in the table below:

 SCHEDULE OF STOCK OPTION ACTIVITY 

    Weighted average  

    Number of  options  
    Exercise  price  
    Remaining  contractual  life  (in years)  
    Intrinsic value 
  
    Outstanding as of January 1, 2025 
     103,114  
    $225.68  
     7.6  
    $- 
  
    Granted 
     3,301  
    $9.24  
     -  
    $4,258 
  
    Forfeited and cancelled 
     (1,749) 
    $-  
     -  
    $- 
  
    Outstanding as of June 30, 2025 
     104,666  
    $125.42  
     7.3  
    $4,258 
  
    Exercisable as of June 30, 2025 
     76,579  
    $158.51  
     6.7  
    $- 
  
    Vested and expected to vest as of June 30, 2025 
     104,666  
    $125.42  
     7.3  
    $4,258 

The
following table summarizes the total stock-based compensation expense included in the unaudited condensed consolidated statements of
operations for the periods presented:

 SCHEDULE OF STOCK BASED COMPENSATION EXPENSES 

    2025  
    2024  
    2025  
    2024 

    For the three months ended  June 30,  
    For the six months ended